Shots:

• The approval is based on the study assessing CAPLYTA (42 mg) vs PBO while keeping Positive and Negative Syndrome Scale (PANSS) as 1EP
• The study resulted in somnolence/sedation (24% vs.10%) and dry mouth (6% vs. 2%)
•  CAPLYTA is a once-daily- oral therapy mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors

Click here to read full press release/ article | Ref: Intra-Cellular | Image: Behance